SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor is drawing attention ahead of the FDAs November 22 target decision on deramiocel for Duchenne muscular dystrophy, with traders weighing whether the amended application and longer-term upper-limb data could support approval. Bullish speculation has been reinforced by commercial-launch job postings and optimism about FDA flexibility, while skeptics cite prior advisory-panel concerns and caution that hiring does not guarantee approval; INOs separate FDA approval has also provided a sentiment tailwind.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,822,022.65079832 with 590,150,211.79771733 in circulation. The last known price of Solana is 94.05303263 USD and is down -1.56 over the last 24 hours. It is currently trading on 1189 active market(s) with $1,556,044,818.54 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is drawing attention amid a broad crypto pullback, with traders debating whether concerns over Binances reported security incident and exchange trust are adding pressure or coinciding with an existing market downtrend. Sentiment is split between bearish calls for further weakness and buyers treating the decline as an opportunity to accumulate and stake.

Cardano (ADA) is a cryptocurrency launched in 2017. Cardano has a current supply of 44,994,665,205.855202 with 36,823,860,963.224877 in circulation. The last known price of Cardano is 0.19280151 USD and is up 0.00 over the last 24 hours. It is currently trading on 1752 active market(s) with $154,401,668.14 traded over the last 24 hours. More information can be found at https://www.cardano.org.

Cardano

ADAs volatile price action and technical levels dominate the discussion, with traders debating whether rebounds and breakout setups can hold or whether further weakness will follow. Sentiment is sharply divided between dip-buying and short-squeeze hopes on one side, and concerns about continued losses and a lack of altcoin momentum on the other.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs record October deliveries, including sharply higher overseas sales, are driving discussion, but traders are debating whether volume growth can translate into better margins and meet the companys Q4 delivery ambitions. The upbeat operating update is being weighed against a steep share-price decline and concerns about China EV competition and profitability.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,809.831273 with 281,866,746.118905 in circulation. The last known price of OFFICIAL TRUMP is 1.73532194 USD and is up 9.97 over the last 24 hours. It is currently trading on 744 active market(s) with $259,407,006.57 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

A modest rebound has prompted pump and short-squeeze chatter around the Trump-themed meme coin, while most discussion focuses on its steep decline and accusations that it is a speculative pump-and-dump. Some holders remain bullish, but skeptics warn of further losses.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention after a sharp selloff alongside AI and optical peers, with traders pointing to broader risk-off sentiment and concerns about dilution, valuation, and execution rather than a clear company-specific setback. Bulls are buying the dip on data-center optics demand and upcoming earnings, while skeptics remain wary of further declines.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a 52-week high ahead of the Q3 report is driving attention, with bullish traders pointing to BRIUMVIs commercial growth and speculating about a short squeeze or buyout. Others caution that the buyout talk is unconfirmed and that the earnings results and upcoming subcutaneous BRIUMVI data will be important tests of the rally.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Positioning around Luckins scheduled third-quarter earnings report is the main focus, with traders hoping for strong results and a rally while others expect a post-report pullback. The debate is amplified by frustration over the stocks prolonged weak, range-bound trading and speculation about buybacks or a future relisting.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons quarterly earnings beat and strong refining results are driving attention, with traders highlighting higher shareholder returns and record-high shares. The reaction is broadly positive, though some caution that the stock looks extended and refining strength may not last if margins normalize.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gileads strong third-quarter results and raised outlook, led by continued HIV drug demand, are driving attention as shares reach fresh highs. Traders are broadly upbeat about the earnings and breakout, though some remain cautious after the run-up.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Analysts Estimate Humana (HUM) to Report a Decline in Earnings: What to Look Out for

Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Humana Board Declares Payment of Quarterly Dividend to Stockholders

Humana Inc. (NYSE: HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on January 29, 2027 to stockholders of record as of the close of business on December 24, 2026. About Humana Humana (NYSE: HUM) is a leading U.S. healthcare...

Centene Q3 Earnings Beat Estimates on Medicare Strength

Centene's Q3 earnings beat estimates as Medicare revenues surge 19.9% despite falling membership, while management lifts its 2026 adjusted profit outlook.

Centene to Report Q3 Earnings: Buy, Sell or Hold the Stock?

CNC's Q3 earnings may face pressure from declining memberships and rising costs, even as improving margins and a 70.7% stock rally offer reasons for optimism.

Humana Gains From Premium Growth Despite Rising Benefit Costs

HUM's surging premiums, Medicare Advantage growth and CenterWell expansion bolster its prospects, but rising benefit costs and expenses pose challenges.

How CVS' Aetna Is Advancing Efforts to Reduce Administrative Burden

CVS Health's Aetna streamlines prior authorizations, approves more than 95% of eligible requests within 24 hours and expands bundled approvals to speed access to care.

Should Value Investors Buy Humana (HUM) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Can UNH's Focus on Special Needs Plans Strengthen Medicare Growth?

UnitedHealth's focus on special needs plans, expanded Medicare coverage and improved margins could drive targeted growth in 2027 despite cost challenges.

Humana's CenterWell Expansion Gets a Boost From BlackRock's Capital

HUM's CenterWell venture with BlackRock brings $2.8 billion in capital, easing balance sheet liabilities and supporting clinic expansion.

Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Oct. 13, 2026Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would...

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

UNH Stock Rises Overnight Ahead Of Earnings: Analyst Outlines ‘Short Premium’ Play To Cut January Call Cost By Nearly 60%

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Khouw’s trade sells November $420 calls and $340 puts to help fund a January 2027 $400 call, lowering its cost by nearly 58%.</li><li>UnitedHealth is expected to post $112.4 billion in Q3 revenue, $6.45 billion in EBITDA and $3.06 in earnings per share.</li><li>Oppenheimer noted that UNH's share of members in four-star-or-higher plans fell 15%, while Humana’s rose to 95% from 42%.</li></ul><p>UnitedHealth (UNH) is set to report third-quarter (Q3) earnings before Tuesday’s market open, with options pricing in a 6.5% move around the results. Tidal Financial Group strategist Michael Khouw says elevated options prices create an opportunity for traders to sell November premium to help finance a cheaper January call.</p><p><a href="https://stocktwits.com/symbol/UNH">UNH stock</a> rose 0.9% in after-hours trading on Monday after closing the regular session down 0.2% at $378.52.</p><h2 class="st-heading-2"><strong>UnitedHealth Options Price In A 6.5% Earnings Move</strong></h2><p>“The only thing more expensive than health insurance is perhaps the costs of insuring shares of health insurers,” Khouw said, pointing to UnitedHealth as an example.</p><p>Options imply a 6.5% move in UnitedHealth shares around earnings, while implied volatility is running at about 40%, about twice the stock’s realized volatility of 20%, he said. The implied move is the second-largest in almost two years. Shares have fallen after five of their past eight earnings reports, including nearly 20% drops after results in January and April 2025, CNBC&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/10/12/unitedhealth-shares-are-doing-something-unusual-ahead-of-earnings.html?taid=6acd105f558573000116c2d1&amp;utm_campaign=trueanthem&amp;utm_content=main&amp;utm_medium=social&amp;utm_source=twitter">noted</a>.</p><h2 class="st-heading-2"><strong>UNH Call Play: How The $400 January Call Trade Cuts Upfront Cost By 58%</strong></h2><p>Khouw’s proposed trade is a “short premium” strategy: It sells two November options to collect $10.60 per share and offset part of the cost of a longer-dated call.&nbsp;</p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Leg&nbsp;</td><td>Trade&nbsp;</td><td>Premium Per Share&nbsp;</td></tr><tr><td>1</td><td>Buy January 2027 $400 Call</td><td>Pay $18.20</td></tr><tr><td>2</td><td>Sell November $420 Call&nbsp;</td><td>Collect $5.80</td></tr><tr><td>3</td><td>Sell November $340 Put</td><td>Collect $4.80</td></tr><tr><td>&nbsp;</td><td>Net Upfront Debit</td><td>$7.60</td></tr></tbody></table></figure></div><p>The trade buys a January 2027 $400 call for $18.20 per share, then sells a November $420 call for $5.80 and a November $340 put for $4.80. The resulting net cost is $7.60 per share, or $760 per contract, reducing the call’s upfront cost by about 58%.&nbsp;</p><h2 class="st-heading-2"><strong>What Could Go Wrong If UNH Moves Sharply?</strong></h2><p>If UnitedHealth finishes November between $340 and $420: The short options would expire worthless. The January call’s breakeven would be $407.60 at expiration.</p><p>If UNH stock falls below $340: The short put could require the seller to buy shares at that price, for an effective cost of about $347.60 per share after the trade’s net debit.</p><p>Khouw said UnitedHealth had been essentially flat over five years and traded 12% to 13% below the midpoint of its two-year high-low range. At about 17 times forward earnings, he said, the stock was not priced for a recovery. He sees the company’s 13% to 16% earnings-growth target as achievable, though rising healthcare costs is a headwind.</p><p>Khouw also pointed to enrollment trends. Affordable Care Act (ACA) marketplace enrollment appears poised to decline, he said, although the segment is smaller than Medicare and commercial coverage. Commercial fee-based enrollment grew about 2.9% from 2024 to 2025, while total Medicare enrollment rose 4.5%. Commercial growth exceeded U.S. workforce growth of about 1.4%.</p><h2 class="st-heading-2"><strong>UNH Q3 Earnings Preview</strong></h2><p>Koyfin’s estimates for the upcoming quarter compare with the last reported quarter. They show revenue of $111.49 billion, down 0.5% sequentially. Earnings before interest, taxes, depreciation and amortization (EBITDA) is estimated at $6.47 billion, down 28%, while earnings before interest and taxes (EBIT) is forecast at $5.44 billion, down 32%. GAAP earnings per share (EPS) are projected to fall 36.81%.</p><p>Fiscal.ai’s year-over-year estimates show revenue of $112.4 billion, compared with $113.2 billion a year earlier. It forecasts EBITDA of $6.45 billion, up from $5.25 billion, and earnings per share of $3.06, compared with $2.92.</p><h2 class="st-heading-2"><strong>Medicare Advantage Ratings: Wall Street Weighs UNH Against Peers</strong></h2><p>TD Cowen lowered its price target on UNH to $402 from $430, implying a 6% upside, while maintaining a 'Buy' rating. The firm expects preliminary commentary on 2027 earnings-per-share expectations with the report.&nbsp;</p><p>Meanwhile, Piper Sandler said 66.8% of UnitedHealth members were enrolled in plans rated four stars or higher, based on September 2026 enrollment data, and called the company’s resilience “impressive” and underappreciated. Oppenheimer noted that the share of members in four-star-or-higher plans fell 15% at UnitedHealth for 2027, versus 10% at Elevance Health, 15% at CVS Health and 9% at Centene. Humana moved in the opposite direction, with 95% of its members in four-star-or-higher plans, up from 42% a year earlier.&nbsp;</p><h2 class="st-heading-2"><strong>How Do Retail Traders Feel About UNH?</strong></h2><p>On Stocktwits, retail sentiment for UNH jumped to ‘extremely bullish’ from ‘bullish’ levels a day ago amid a 1,680% surge in 24-hour message volumes.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/unh_ss_d30ab9f499.png" alt="unh ss.png" width="633" height="342"><figcaption>UNH sentiment and message volume as of October 13 | Source: Stocktwits</figcaption></figure><p>One user&nbsp;<a href="https://stocktwits.com/Jimsonlima/message/666329330">said</a>, “$UNH beat and raise. 500 incoming”</p><p><stembedurl>https://stocktwits.com/Jimsonlima/message/666329330</stembedurl></p><p>Another user&nbsp;<a href="https://stocktwits.com/Bobky2030/message/666326375">said</a>, “$UNH be cool to beat huge and raise. Shorts have to chase to 435.00 plus this week.”</p><p><stembedurl>https://stocktwits.com/Bobky2030/message/666326375</stembedurl></p><p>UNH stock has risen 17% year-to-date.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-bull-trap-risk-holds-back-new-shorts-trump-fannie-freddie-call/cZxBdKIRBob">‘The Trick Is To Get There’: Michael Burry Sees ‘Bull Trap’ Risk But Holds Back On New Shorts&nbsp;</a></p>

In this photo illustration, the UnitedHealth Group logo is displayed on the screen of a smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Tidal Financial Group strategist Michael Khouw says options imply a 6.5% earnings move, with implied volatility at 40%, twice the stock’s realized volatility.

Centene Corp.

CVS Health Corp

Elevance Health Inc

Humana Inc

Unitedhealth Group Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$414.50
Prev Close	$416.68
Open	$415.66
Dividend Yield	1.38%
50-Day Moving Average	$401.03
Beta	0.41
Avg. Volume	1.06M
PE Ratio	39.25

52-Week High	$456.50
52-Week Low	$163.11
Market Capitalization	$49.77B
EPS (Annual)	$9.83
Price to Book	2.59
Revenue Per Employee	$1.93M

Feed

News

Sentiment

Earnings

Fundamentals

Info

HUM Fundamentals